Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Common Equity (2016 - 2026)

Champions Oncology has reported Common Equity over the past 16 years, most recently at $4.3 million for Q1 2026.

  • For Q1 2026, Common Equity fell 21.69% year-over-year to $4.3 million; the TTM value through Jan 2026 reached $4.3 million, down 21.69%, while the annual FY2025 figure was $3.8 million, 298.21% up from the prior year.
  • Common Equity for Q1 2026 was $4.3 million at Champions Oncology, up from $4.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $9.2 million in Q1 2022 and troughed at -$2.1 million in Q1 2024.
  • A 5-year average of $4.0 million and a median of $4.2 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 141.05% in 2024 and later skyrocketed 1165.66% in 2025.
  • Year by year, Common Equity stood at $9.2 million in 2022, then tumbled by 98.99% to $93000.0 in 2023, then skyrocketed by 632.26% to $681000.0 in 2024, then surged by 521.29% to $4.2 million in 2025, then grew by 1.23% to $4.3 million in 2026.
  • Business Quant data shows Common Equity for CSBR at $4.3 million in Q1 2026, $4.2 million in Q4 2025, and $3.5 million in Q3 2025.